Genetic factors, such as LRRK2 variants, further complicate NMS progression, yet transcriptomic analyses of genotype–phenotype interactions in non-motor domains are scarce (Deng et al., 2019). The gene discussed is LRRK2; the disease is neuroleptic malignant syndrome.